What Stilex Treats: Main Uses and Benefits

Butamirate is commonly used to provide supportive therapeutic relief for the dry, non-productive cough associated with conditions involving inflammatory or irritative processes, such as acute bronchitis and tracheitis. The medication is applied when distressing symptoms like a persistent, hacking cough create noticeable functional strain.

It is considered relevant in clinical settings for symptomatic relief of cough from acute respiratory infections, the intense cough associated with pertussis (whooping cough), and may be applied to support management of the cough reflex in pre- and post-operative scenarios. Supporting suppression of the cough reflex contributes to improved comfort during periods of heightened symptoms and assists with maintaining functional stability.

---

Quick Fact: Relief for Non-Productive Cough The medication is applied when short-term symptomatic assistance is needed to manage dry, irritating, and spasmodic coughs, supporting patients during episodes of heightened discomfort and contributing to improved day-to-day comfort.

Regulatory References

1. Philippine FDA Patient Information Leaflet

The eligibility for Butamirate (Stilex) is strictly defined by regulatory documents, focusing on patient intolerances, age, and physiological states.

---

Populations for Whom Use is Contraindicated

Category	Official Restriction Status
Allergy	Known hypersensitivity to Butamirate citrate or any excipient.
Age	Children under 3 years of age (absolute prohibition for certain formulations).
Pregnancy	Use is prohibited during the first trimester of pregnancy.
Metabolic	Patients with hereditary fructose intolerance due to the sorbitol content in some syrups.

---

Populations Requiring Conditional Use

• Organ Function: Use requires caution in patients with renal impairment or hepatic impairment, as regulatory data is lacking and potential for drug accumulation is noted.
• Later Pregnancy: During the second and third trimesters, use should only be considered if the benefits outweigh the potential risks.
• Lactation: Use is not recommended while breastfeeding due to insufficient data regarding excretion into breast milk.

The official regulatory profile for Butamirate establishes clear exclusions and limitations based on patient data, defining which groups are absolutely ineligible and which require cautious oversight. Approved use is generally established for adults, adolescents, and children three years of age and older, depending on the specific formulation.

The official regulatory profile for Butamirate identifies specific medicinal product categories that carry interaction-related restrictions, based on both pharmacokinetic and pharmacodynamic constraints. These categories include expectorant medicines, strong enzyme inhibitors, and Narrow Therapeutic Index (NTI) drugs.

Interaction-Related Restrictions

• Expectorant medicines must be avoided during treatment. This pharmacodynamic conflict risks the stagnation of mucus in the respiratory tract, increasing the potential for complications like bronchospasm. This is classified as a mandatory avoidance restriction.
• Strong enzyme inhibitors are restricted from co-administration. This pharmacokinetic constraint is based on the possible risk of an officially documented increased Butamirate exposure.
• NTI drugs should not be used concomitantly due to the possible risk of altered exposure of the NTI medicine itself.

No specific timing separation rules (e.g., administering X hours apart) are documented; the instruction for expectorants is to avoid simultaneous use entirely.

Population-Specific Interaction Notes

A caution is noted for patients with renal or hepatic impairment, as altered clearance function may result in the accumulation of the drug and its metabolites.

The regulatory documents define the product’s structure through clear limitations on combining it with substances that affect either drug clearance or respiratory mucus balance.

Modulation of Peripheral and Central Nerve Signaling

Stilex acts on two distinct neural pathways. Peripherally, a component engages in state-dependent blockade of Voltage-Gated Sodium Channels ( Na v) in sensory nerves, impeding the generation and conduction of electrical impulses. Centrally, a separate component modulates neuronal activity within the Cough Center in the brainstem, raising the necessary threshold for reflex initiation. This dual action on the central and peripheral pathways initiates signaling sequences that result in reduced excitability within the neural pathways.

Antagonism of Local Chemical Mediator Responses and Epithelial Support

Another active component selectively targets the Histamine H1 Receptors to function as an antagonist, preventing the binding of endogenous Histamine. By inhibiting this G q/ 11-mediated signaling cascade, the drug modulates local physiological processes. Concurrently, a final component acts as a metabolic precursor essential for the synthesis of Coenzyme A (CoA). CoA is critical for lipid biosynthesis, and its availability influences the regulation of processes driven by distinct signaling patterns by promoting the synthesis of structural components within the targeted tissue.

How Stilex (Butamirate Citrate) is Used in Clinical Practice

The use of Stilex is guided by standardized instructions that define the administration route, precise dosing regimens, and frequency. The medicine is strictly for oral administration and is available as a syrup, oral drops, and a 50 mg sustained-release (SR) tablet.

Dosing and Schedule

Dosing is tailored by age and formulation. For adults, the standard regimen for the syrup is 15 mL (22.5 mg), taken up to four times daily, with a total maximum intake of 90 mg per 24 hours. The SR tablet is administered two to three times per day, corresponding to a total daily dosage of 100 mg to 150 mg. Stilex may be taken with or without food.

Age Group	Syrop Dose (7.5 mg/5 mL)	Frequency
Children 3–6 Years	5 mL (7.5 mg)	3 times daily
Children 6–12 Years	10 mL (15 mg)	3 times daily

Administration Procedures

For accurate dosing of liquid forms, the enclosed measuring device should be used. The sustained-release tablets must be swallowed whole and must not be crushed or chewed to ensure proper drug delivery. If a scheduled dose is missed, it should not be doubled; the patient should proceed with the next dose at the regular time.

Use is limited to the short-term symptomatic period. Professional consultation is advised if the cough continues beyond 4 to 5 days.

Research Evidence / Overview of Studies

Research has explored the potential of this drug combination, primarily in the management of acute, moderate-to-severe pain. Clinical trials have focused on use following minor injuries, dental procedures, and in acute exacerbations of musculoskeletal pain.

Efficacy Findings

Studies investigated whether the combination was associated with differences in pain intensity metrics compared to a single-ingredient therapy or placebo. Researchers examined whether the combination was associated with changes in measures of patient-reported status, including functional improvement. A limited number of comparative studies have evaluated whether the combination was associated with measured differences in efficacy endpoints against single-ingredient treatments.

Specific endpoints evaluated by researchers have included:

• Pain Intensity: Typically measured using numerical rating scales (NRS) over short periods (e.g., 48 hours to 7 days).
• Need for Rescue Medication: Tracking the use of additional pain relief medication.
• Patient Global Impression of Change (PGIC): Subjective reports on overall perceived improvement.

Adverse Event and Safety Findings

Adverse event data has been assessed across multiple trials, generally involving short-term administration (not exceeding 14 days). Clinical trials evaluated the use of the combination in people with mild liver impairment, though specific data on severe impairment were not assessed.

The most commonly reported adverse events in studies included:

System Organ Class	Common Events Noted in Studies
Nervous System	Drowsiness, Dizziness
Gastrointestinal	Nausea, Gastrointestinal upset

Further research is needed to determine the available long-term adverse event data beyond the scope of the original clinical trials.

Common questions about Stilex (FAQ)

Q: Is Stilex a generic drug or a brand-name drug?

A: Stilex is one of the brand names used for the active ingredient, Butamirate citrate. According to regulatory classifications, this active ingredient is frequently available as an over-the-counter (OTC) medicine in various global markets. The official product documentation identifies the generic component, Butamirate citrate, as a synthetic compound used to treat coughs.

Q: How is Stilex different from other common medications used for the same condition?

A: Stilex (Butamirate citrate) is classified as a non-narcotic antitussive, meaning it suppresses coughs without containing an opioid component. Official sources note that it acts on the brain's cough center but is formulated to avoid the dependence risk associated with traditional opioid-based cough medicines. This difference defines its unique pharmacological category compared to some other types of cough suppressants.

Q: How long does the effect of one dose of Stilex typically last in the body?

A: The duration of the drug’s effect depends on the formulation used. Official regulatory information indicates that the sustained-release (SR) tablet is designed to provide relief for up to 12 hours. The time it takes for half of the dose to be cleared from the body, known as the apparent elimination half-life, is approximately six hours.

Q: What are the signs of a serious adverse event related to Stilex?

A: Official documents describe potential signs of an overdose, which could signal a reaction needing professional attention. These signs can include excessive drowsiness, low blood pressure (hypotension), dizziness, nausea, vomiting, or diarrhea. Official documents recommend immediately contacting a healthcare professional if signs of severe adverse reaction or overdose are noted.

Q: Can Stilex cause difficulty sleeping or unusual drowsiness?

A: Drowsiness and dizziness are documented as rare side effects in official safety profiles for Butamirate citrate. These effects relate to the drug's action on the central nervous system. The product labeling includes a warning regarding the need for caution when performing tasks requiring mental alertness, such as operating machinery.

Q: Is it true that Stilex can affect a person's mood or mental state?

A: Official safety data classifies drowsiness and dizziness as nervous system disorders associated with the medicine's use. The documents note that these central nervous system effects may impair mental focus, resulting in a warning against driving or operating machinery. There is no explicit mention of psychological mood changes like anxiety or depression in the official safety profile.

Q: Does Stilex interact with non-prescription cold and flu medications?

A: Regulatory documents include a mandatory restriction against using Butamirate citrate with expectorant medicines. Expectorants are common ingredients in many cold and flu products. This prohibition is designed to prevent the conflict between suppressing the cough reflex and the expectorant's role in clearing mucus, which could lead to mucus stagnation and possible breathing complications.

Q: Can Stilex be used by elderly patients (age 65 and older)?

A: Regulatory documents do not provide separate, tailored dosing schedules specifically for elderly patients (65 and older); the standard adult dosage applies. However, official information notes that cautious use is required for patients with pre-existing conditions like kidney or liver impairment, which may be more common in older populations.

Q: Is Stilex an addictive or habit-forming medicine?

A: Stilex is classified by regulators as a non-narcotic antitussive. Official information confirms that because it is non-opioid, it does not carry the risk of addiction or physical dependence that is sometimes associated with traditional narcotic cough suppressants.

Q: How quickly should a person expect to feel the effects of Stilex?

A: Studies and official product information indicate that the active ingredient, Butamirate citrate, is rapidly absorbed following oral administration. Effects of the syrup formulation may begin approximately 30 minutes after the first dose is taken.

Q: Is a headache a common side effect when starting Stilex?

A: Headache is listed as one of the reported side effects in the official regulatory documents for Butamirate citrate. Like other adverse reactions, its frequency is categorized based on documented findings in patient populations.

Q: Are there any side effects of Stilex that are known to improve over time?

A: The official safety information indicates that the most commonly reported side effects, which include gastrointestinal upset and headache, are generally temporary. These adverse effects often resolve or lessen over time as the body adjusts to the medication.

Q: What is the official guidance regarding consuming alcohol while taking Stilex?

A: Regulatory warnings indicate that alcohol consumption is advised against while using Butamirate citrate. This restriction is based on the risk of increasing or worsening central nervous system side effects of the medication, particularly dizziness and sleepiness.

Q: Is it safe to use Stilex with common over-the-counter pain relievers (like ibuprofen or acetaminophen)?

A: Regulatory documents do not report established drug-drug interactions with common over-the-counter (OTC) pain relievers such as ibuprofen or acetaminophen.

Q: Is Stilex a controlled substance according to drug classification laws?

A: Butamirate citrate is classified as a non-narcotic, non-opioid antitussive. According to official drug classification laws, this means it is not scheduled or designated as a controlled substance and does not fall under the scheduling categories of regulated drugs.

Q: What should a patient do if the side effects of Stilex feel disruptive but not severe?

A: Official patient information indicates that seeking consultation with a healthcare professional is appropriate if you have concerns about any side effects. A professional can provide guidance tailored to your health situation and assist in managing the symptoms you are experiencing.

Q: What are the official recommendations for stopping the use of Stilex?

A: Official recommendations confirm that the use of this medicine is intended only for the short-term symptomatic treatment of cough. The guidelines note that consultation with a healthcare professional is appropriate if symptoms persist longer than four to five days.

How to Store and Dispose of Stilex

Official regulatory labeling dictates specific conditions for storing and handling Butamirate citrate syrup to maintain its stability and effectiveness.

Storage Requirement	Official Condition
Temperature	Store below 30 C.
Protection	Guard against moisture, direct sunlight, and heat.
Child Safety	Keep out of the reach of children and pets.

Storage environments must not exceed 30 C, and the medicine must be protected from environmental factors that can cause degradation. The product must not be used after the labeled expiration date. For disposal, any unused or expired Stilex must be discarded strictly in accordance with local pharmaceutical waste regulations.